Tixylix Honey, Lemon & Glycerol oral solution

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Honey; Glycerol; Liquid sugar demineralised

Pieejams no:

Novartis Consumer Health UK Ltd

ATĶ kods:

n/a

SNN (starptautisko nepatentēto nosaukumu):

Honey; Glycerol; Liquid sugar demineralised

Deva:

222microgram/1ml ; 150microlitre/1ml ; 440microlitre/1ml

Zāļu forma:

Oral solution

Ievadīšanas:

Oral

Klase:

No Controlled Drug Status

Receptes veids:

Never Valid To Prescribe As A VMP

Produktu pārskats:

BNF: 03090200; GTIN: 5051562014405 5051562031808

Produkta apraksts

OBJECT 1
TIXYLIX HONEY, LEMON & GLYCEROL ORAL SOLUTION
Summary of Product Characteristics Updated 01-Apr-2016 |
GlaxoSmithKline Consumer Healthcare
1. Name of the medicinal product
Glycerin, Honey and Lemon Linctus
Glycerin, Honey and Lemon Soothing Cough Syrup
Tixylix Honey, Lemon & Glycerol Oral Solution
2. Qualitative and quantitative composition
Active ingredients
Honey
Glycerin Ph Eur
Liquid sugar
per 5ml
1.11g
0.75ml
2.2ml
3. Pharmaceutical form
Oral solution
4. Clinical particulars
4.1 Therapeutic indications
For the relief of coughs and sore throats.
4.2 Posology and method of administration
For oral administration.
Adults and children over 12
years
Children 5-12 years
Children 1 to 5 years
l0ml
5ml
2.5ml
The dose may be taken up to three or four times a day, if needed.
Elderly There is no need for dosage reduction in the elderly.
4.3 Contraindications
Hypersensitivity or intolerance to any of the ingredients.
4.4 Special warnings and precautions for use
If symptoms persist consult your doctor.
Keep all medicines out of the reach of children.
4.5 Interaction with other medicinal products and other forms of
interaction
No clinically significant drug interactions known.
4.6 Fertility, pregnancy and lactation
The safety of Glycerin, Honey and Lemon Linctus during pregnancy and
lactation has not been
established, but it is not considered to constitute a hazard during
these periods.
4.7 Effects on ability to drive and use machines
No known adverse effects.
4.8 Undesirable effects
Immune system disorder: hypersensitivity reactions, including
anaphylaxis.
REPORTING OF SUSPECTED ADVERSE REACTIONS
Reporting suspected adverse reactions after authorisation of the
medicinal product is important. It allows
continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are
asked to report any suspected adverse reactions via the Yellow Card
Scheme at
www.mhra.gov.uk/yellowcard.
4.9 Overdose
Overdosage is unlikely to present a problem and treatment need only be
symptomatic.
5. Pharmac